Copyright © 2016 Advantagene, Inc.  All rights reserved. Made by AFP.    Terms of use | Privacy policy


1. Phase 2 multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.

Wheeler LA, Manzanera AG, Bell SD, Cavaliere R, McGregor JM, Grecula JC, Newton HB, Lo SS, Badie B, Portnow J, Teh BS, Trask TW, Baskin DS, New PZ, Aguilar LK, Aguilar-Cordova E, Chiocca EA.

Neuro Oncol. 2016 Feb 2. pii: now002. [Epub ahead of print]


2. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.

Aguilar LK, Shirley LA, Chung VM, Marsh CL, Walker J, Coyle W, Marx H, Bekaii-Saab T, Lesinski GB, Swanson B, Sanchez D, Manzanera AG, Aguilar-Cordova E, Bloomston M.

Cancer Immunol Immunother. 2015 Jun;64(6):727-36. doi: 10.1007/s00262-015-1679-3. Epub 2015 Mar 21.


3. Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer.

Rojas-Martínez A, Manzanera AG, Sukin SW, Esteban-María J, González-Guerrero JF, Gomez-Guerra L, Garza-Guajardo R, Flores-Gutiérrez JP, Elizondo Riojas G, Delgado-Enciso I, Ortiz-López R, Aguilar LK, Butler EB, Barrera-Saldaña HA, Aguilar-Cordova E.

Cancer Gene Ther. 2013 Nov;20(11):642-9. doi: 10.1038/cgt.2013.56. Epub 2013 Sep 20.


4. The spectrum of vaccine therapies for patients with glioblastoma multiforme.

Aguilar LK, Arvizu M, Aguilar-Cordova E, Chiocca EA.

Curr Treat Options Oncol. 2012 Dec;13(4):437-50. doi: 10.1007/s11864-012-0208-2. Review.


5. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.

Aguilar LK, Guzik BW, Aguilar-Cordova E.

J Cell Biochem. 2011 Aug;112(8):1969-77. doi: 10.1002/jcb.23126. Review.


6. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer.

Ayala G, Satoh T, Li R, Shalev M, Gdor Y, Aguilar-Cordova E, Frolov A, Wheeler TM, Miles BJ, Rauen K, Teh BS, Butler EB, Thompson TC, Kadmon D.

Mol Ther. 2006 Apr;13(4):716-28. Epub 2006 Feb 15.


7. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients.

Fujita T, Teh BS, Timme TL, Mai WY, Satoh T, Kusaka N, Naruishi K, Fattah EA, Aguilar-Cordova E, Butler EB, Thompson TC.

Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):84-90. Epub 2006 Feb 10.



Additional publications are available at http://www.ncbi.nlm.nih.gov/pubmed/

Selected Clinical Publications